PRAME (E7I1B) Rabbit Monoclonal Antibody (SignalFlex™ Pacific Blue™ Conjugate) #89850
Product Specifications
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | |
| Source/Isotype | Rabbit IgG |
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Description
This Cell Signaling Technology® antibody is conjugated to Pacific Blue™ fluorescent dye under optimal conditions and formulated at 200 µg/mL. This antibody conjugate is expected to exhibit the same species cross-reactivity as the unconjugated #56426
Fluorescent Properties
- ← Excitation: 410 nm ← Emission: 455 nm
Product Usage Information
SignalFlex™ conjugates are produced using highly validated Cell Signaling Technology® primary antibodies and conjugation methods that have been rigorously tested, ensuring high-quality conjugates and lot-to-lot consistency. These conjugates are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. However, they are not tested on specific assays.
Optimal dilutions/concentrations should be determined by the end user. When performing flow cytometry, we recommend using an isotype control conjugate at the same concentration as the antibody conjugate.
Storage
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
PRAME (preferentially expressed antigen in melanoma) is a cancer/testis antigen not normally expressed in any tissues except testis, but is upregulated in tumors. PRAME is expressed in melanoma cells and is recognized by cytolytic T-cells (4). It is also upregulated in other diseases, such as synovial sarcoma (5), NSCLC (6), and breast cancer, where it is thought to contribute to tumorigenesis and metastasis (7). PRAME is also highly expressed in liquid tumors such as AML (8) and can be predictive of clinical outcome in some circumstances (9). PRAME and other cancer/testis antigens are currently being pursued as novel immunotherapy targets and diagnostic biomarkers (10).
- Caballero, O.L. and Chen, Y.T. (2009) Cancer Sci 100, 2014-21.
- De Smet, C. et al. (1999) Mol Cell Biol 19, 7327-35.
- Gjerstorff, M.F. et al. (2015) Oncotarget 6, 15772-87.
- Ikeda, H. et al. (1997) Immunity 6, 199-208.
- Iura, K. et al. (2017) Hum Pathol 61, 130-139.
- Gunn, R.B. and Fröhlich, O. (1989) Methods Enzymol 173, 54-80.
- Sun, Z. et al. (2016) Gene 594, 160-164.
- Qin, Y.Z. et al. (2017) Oncol Lett 13, 2823-2830.
- Oehler, V.G. et al. (2009) Blood 114, 3299-308.
- Salmaninejad, A. et al. (2016) Immunol Invest 45, 619-40.
Alternate Names
cancer/testis antigen 130; CT130; MAPE; Melanoma antigen preferentially expressed in tumors; OIP-4; OIP4; Opa-interacting protein 4; Opa-interacting protein OIP4; PRAME; PRAME nuclear receptor transcriptional regulator; preferentially expressed antigen in melanoma; Preferentially expressed antigen of melanoma
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专